ROCM

Overview

Highlights

News

Chart

Contacts

 

   
 
   
"Announced a 63% increase in sales revenues for the current quarter compared to last year's first quarter  
   
   
Approximate Financial Snapshot as of 3/19/07
Shares Outstanding 11.34M
52 Wk Hi/Lo 19.59/

5.50

Market Cap $207.6M
Recent Price $18.30

 

 

3/19/07

Rochester Medical (ROCM)

Website: www.rocm.com

A study at the Johns Hopkins Burn Center showed infection rates fell 70% when doctors switched from using uncoated latex catheters to Rochester's device.


Overview

Rochester Medical (ROCM) develops, manufactures, and markets innovative urinary continence and urine drainage care products for the extended care and acute care markets in the United States and internationally. Its extended care products include a line of male external catheters for managing male urinary incontinence and a line of intermittent catheters for managing both male and female urinary retention. 

The company's extended care products also comprise the FemSoft Insert, a liquid-filled and conformable urethral insert for managing female stress urinary incontinence in adult females; and Personal Catheters, a line of disposable intermittent catheters manufactured from silicone in three lengths with multiple diameters for male, female, and pediatric use. Its acute care products comprise a line of Foley catheters, including Release-NF catheter, an antibacterial Foley catheter that reduces the incidence of hospital acquired urinary tract infection. 

RMC offers silicone Foley catheters in a two-lumen version for urinary drainage management and in a three-lumen version that also supports irrigation of the urinary tract. It also provides antibacterial and hydrophilic intermittent catheters. In addition, the company manufactures and sells male external catheters made from proprietary non-latex and non-silicone material to certain private label customers. It sells its products under the Rochester Medical brand name through direct sales force, primarily for distributors, extended care facilities, individual hospitals, and healthcare institutions in the United States; and through independent distributors internationally.

This is an abbreviated profile and we encourage readers interested in learning more about Rochester Medical to visit the company website at www.rocm.com.


ROCM Investor Highlights

  • Reported record sales of $7,512,000 for the quarter ending 12/31/06 compared to $4,607,000 for the first quarter of last year. It also reported net income of $31,467,000 or $2.59 per diluted share compared to a net income of $311,000 or $.03 per diluted share for the first quarter of last year.
  • Quarterly results include $38,605,000 of income resulting from the previously announced lawsuit settlements.
  • The 63% increase in sales revenues for the current quarter compared to last year's first quarter resulted from increased Rochester Medical Brand sales, primarily attributable to increased international sales of Rochester Medical Brand products resulting from the previously announced acquisition in the United Kingdom, and also from increased Private Label sales.
  • "This has certainly been an eventful quarter," said Company CEO and President Anthony J. Conway. "We were awarded a National Group Purchasing Contract by Premier Purchasing Partners, L.P.; we renewed our Private Label sales agreement with Hollister, Inc.; we secured two lawsuit settlements in our anti-trust litigation; and we realized strong sales and earnings. We are pleased with the Company's progress, and we look forward to a good year."
  • Announced that it has signed a new Private Label Agreement for supply of Male External Catheters (MECs) to Hollister Incorporated and also announced that the parties have amended their 2003 OEM/Private Label Agreement.The MEC Agreement has a five year term commencing on January 1, 2007. Under the Agreement Rochester Medical will continue to supply Hollister with its requirements of non-latex Male External Catheters for sale under the Hollister brand worldwide, excluding the United Kingdom.
  • Announced that group purchasing organization, Premier Purchasing Partners, L.P. ("Premier") has awarded the Company a national contract for supplying Premier's participating members with urological products, including Rochester Medical's line of infection control catheters. Premier is one of the largest Group Purchasing Organizations in the United States with over $27 billion in contract purchases per year. Its members include more than 1,500 hospital facilities and hundreds of other care sites. The contract has a 27 month term from the effective date of March 1, 2007. Initial marketing efforts are expected to commence prior to that date. 

Recent News and Press Releases

Battle Scarred

Rochester Medical Reports Record First Quarter

Rochester Medical Corporation Announces Settlement Agreement With C.R. Bard, Inc.

Rochester Medical Announces Agreements With Hollister Incorporated

Rochester Medical Corporation Announces Settlement Agreement With Premier

Rochester Medical Corporation Awarded National Group Purchasing Contract for Urological Products

For the latest Quote and News on ROCM Click Here.


Three Month Chart




Outlook

Rochester Medical Corporation, a small-cap growth company in the health care sector, is expected to significantly outperform the market over the next six months with average risk. Source MSN


Contacts

Rochester Medical Corp.

One Rochester Medical Drive
Stewartville, MN 55976
Phone: 507-533-9600
Fax: 507-533-4232


SEC Filings

ROCM filings with the SEC can be found here. All Fillings are current and the Company is fully reporting.


Disclaimer

SmallCapReview.com feature stock reports are intended to be stock ideas, NOT recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. For continuing coverage of ROCM, please sign up for our free newsletter. Information contained in this report was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. For more information see our disclaimer section, a link of which can be found on our web site. This document contains forward-looking statements, particularly as related to the business plans of the Company, within the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Actual results may differ materially from the Company's expectations and estimates. The information provided in this report is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country.

Copyright SmallCapReview.com. All rights reserved. SmallCapReview.com is not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All materials presented on our web site and individual reports released to the public through this web site, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with any stock, companies we select to profile involve a degree of investment risk and volatility. Particularly Small-Caps and OTC-BB stocks. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. Past performance of our profiled stocks is not indicative of future results. The accuracy or completeness of the information on our web site or within our reports is only as reliable as the sources they were obtained from. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. SmallCapReview.com may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our web site or within our reports. In order to be in full compliance with the Securities Act  of 1933, Section 17(b), SmallCapReview.com will disclose in it's disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the SmallCapReview.com web site. SmallCapReview.com has not been compensated for its efforts in presenting the Rochester Medical profile on its website and distributing it to its database of subscribers. SmallCapReview.com may decide to purchase or sell shares on a voluntary basis in the open market before, during or after the profiling period of this report. Information presented on our web site and within our reports contain "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as “expects’”, “will,” “anticipates,” “estimates, “believes,” or that by statements indicating certain actions “may,” “could,” or “might” occur.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at: http://www.sec.gov and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com . Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.